Q3 Earnings Estimate for Entera Bio Issued By HC Wainwright

Key Points

• HC Wainwright projects Entera Bio's Q3 2025 earnings per share (EPS) at ($0.09), maintaining a "Strong-Buy" rating for the stock.
• Entera Bio recently reported a Q2 EPS of ($0.06), outperforming the consensus estimate of ($0.11) by $0.05.
• Institutional ownership of Entera Bio is currently at 14.11%, with significant recent increases in holdings by multiple hedge funds.

Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Entera Bio in a report issued on Monday, August 11th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.09) for the quarter. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for Entera Bio's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Entera Bio's Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.32) EPS.

Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.05. Entera Bio had a negative return on equity of 77.75% and a negative net margin of 4,525.11%.

Entera Bio Price Performance

Shares of NASDAQ:ENTX opened at $1.94 on Thursday. Entera Bio has a 1-year low of $1.50 and a 1-year high of $2.79. The business has a fifty day moving average price of $1.95 and a 200-day moving average price of $2.00. The company has a market capitalization of $88.58 million, a PE ratio of -7.46 and a beta of 1.52.

Hedge Funds Weigh In On Entera Bio

Several institutional investors and hedge funds have recently modified their holdings of ENTX. Knoll Capital Management LLC increased its holdings in shares of Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after acquiring an additional 2,000,000 shares in the last quarter. Northern Trust Corp bought a new position in shares of Entera Bio during the fourth quarter valued at $450,000. Bessemer Group Inc. bought a new position in shares of Entera Bio during the second quarter valued at $268,000. Parkman Healthcare Partners LLC increased its holdings in shares of Entera Bio by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock valued at $747,000 after acquiring an additional 25,900 shares in the last quarter. Finally, HighTower Advisors LLC increased its holdings in shares of Entera Bio by 53.3% during the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock valued at $31,000 after acquiring an additional 6,310 shares in the last quarter. 14.11% of the stock is currently owned by institutional investors.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.